<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687410</url>
  </required_header>
  <id_info>
    <org_study_id>H-20006798</org_study_id>
    <nct_id>NCT04687410</nct_id>
  </id_info>
  <brief_title>Novel Crown-cut Biopsy Needle (FNB) vs Standard Aspiration Needle (FNA) for EUS-guided Diagnosis of SPLs</brief_title>
  <official_title>Randomized Comparison of Tissue Quality and Molecular Yield Between a Novel Crown-cut Biopsy Needle (FNB) and a Standard Aspiration Needle (FNA) for EUS Guided Diagnosis of Solid Pancreatic Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peter Vilmann MD, DSc, HC, FASGE</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gastro Unit, Endoscopy Section, Hvidovre Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Department of Gastroenterology, Ponderas Academic Hospital Bucharest, Romania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Endoscopy Unit, Odense Hospital, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare tissue quality and molecular yield between a novel&#xD;
      crown-cut biopsy needle (FNB) and a standard aspiration needle (FNA) for EUS-guided diagnosis&#xD;
      of solid pancreatic lesions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of tissue micro-fragments</measure>
    <time_frame>1 month</time_frame>
    <description>Comparison of median number of tissue micro-fragments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic tissue area</measure>
    <time_frame>1 month</time_frame>
    <description>Comparison of total diagnostic tissue area in um2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Total tissue area</measure>
    <time_frame>1 month</time_frame>
    <description>Comparison of total total tissue area in um2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic yield</measure>
    <time_frame>1 month</time_frame>
    <description>diagnostic yield - defined by percentage of diagnostic samples in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic performance</measure>
    <time_frame>12 month</time_frame>
    <description>Sensitivity and specificity, where final diagnosis is either established by subsequent histopathological confirmation or other evidence (clinical, radiological) of malignant disease at a minimum of 12 months of follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>1 month</time_frame>
    <description>Comparison of proportions of patients experiencing AE in each group as defined by ASGE's lexicon on adverse events in endoscopy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean DNA concentration</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Suitability for molecular analyses</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of samples where NGS analysis was successful</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Pancreas Neoplasm</condition>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>FNA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FNB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ProControl, MediGlobe</intervention_name>
    <description>standard 22G FNA needle</description>
    <arm_group_label>FNA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TopGain, Medi-Globe</intervention_name>
    <description>novel 22G crown-cut FNB needle</description>
    <arm_group_label>FNB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with a newly discovered SPL scheduled for EUS-guided tissue acquisition&#xD;
             who can understand and provide a written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with uncorrected coagulopathies (INR &gt;1.5 or platelet count &lt;50,000) or&#xD;
             patients treated with anticoagulants that cannot be discontinued.&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Interposed, large vessels between the transducer and the target lesion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bojan Kovacevic</last_name>
    <phone>+4538686312</phone>
    <email>bojan.kovacevic@regionh.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gastro Unit, Division of Endoscopy</name>
      <address>
        <city>Herlev</city>
        <state>Danmark</state>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bojan Kovacevic, MD</last_name>
      <phone>+4538686312</phone>
      <email>bojan.kovacevic@regionh.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Peter Vilmann MD, DSc, HC, FASGE</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>fine needle aspiration</keyword>
  <keyword>fine needle biopsy</keyword>
  <keyword>solid pancreatic lesion</keyword>
  <keyword>pancreatic neoplasm</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>endoscopic ultrasound</keyword>
  <keyword>EUS-FNA</keyword>
  <keyword>EUS-FNB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

